Is Silence Therapeutics plc (NASDAQ:SLN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Silence Therapeutics plc at current levels.
A $327M market cap sitting on top of two Phase 2 siRNA programs, either of which could re-rate the whole company.
Where SLN is headed
By the back half of 2027, Silence Therapeutics is no longer a forgotten London-listed siRNA story trading at cash-plus-a-bit. It is either a takeout target with a Phase 3-ready Lp(a) asset (zerlasiran) competing in a market Novartis and Eli Lilly have already validated as worth billions, or it is the polycythemia vera disruptor that finally gives hematologists an alternative to phlebotomy and ruxolitinib. The current $327M enterprise value implies the market is pricing in roughly one of these working at low probability. Both programs hitting changes the math entirely.
Read the full Compass Direction on SLN
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $6.20).
See the full SLN analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Silence Therapeutics plc (NASDAQ:SLN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Silence Therapeutics plc at current levels. A $327M market cap sitting on top of two Phase 2 siRNA programs, either of which could re-rate the whole company.
What is SLN's Compass Score?
Silence Therapeutics plc scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for SLN?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the SLN page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.